Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13506MR)

This product GTTS-WQ13506MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13506MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11259MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ9119MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ684MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ6943MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ14681MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ4539MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ9437MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ12166MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW